AbbVie Inc (ABBV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AbbVie Inc (ABBV) has a cash flow conversion efficiency ratio of -1.616x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($5.22 Billion) by net assets ($-3.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AbbVie Inc (ABBV) market capitalisation for the company's overall valuation and market capitalisation.
AbbVie Inc - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how AbbVie Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AbbVie Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AbbVie Inc ranked by their cash flow conversion efficiency. Explore how high is AbbVie Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chevron Corp
NYSE:CVX
|
0.013x |
|
Caterpillar Inc
NYSE:CAT
|
0.168x |
|
The Coca-Cola Company
NYSE:KO
|
0.144x |
|
Berkshire Hathaway Inc
NYSE:BRK-A
|
0.014x |
|
HSBC Holdings plc
MX:HBCN
|
N/A |
|
Procter & Gamble Company
NYSE:PG
|
0.093x |
|
UnitedHealth Group Incorporated
NYSE:UNH
|
0.104x |
|
Lam Research Corp
NASDAQ:LRCX
|
0.108x |
Annual Cash Flow Conversion Efficiency for AbbVie Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of AbbVie Inc from 2010 to 2025. View AbbVie Inc (ABBV) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-3.23 Billion | $19.03 Billion | -5.895x | -205.45% |
| 2024-12-31 | $3.36 Billion | $18.81 Billion | 5.590x | +154.49% |
| 2023-12-31 | $10.40 Billion | $22.84 Billion | 2.197x | +52.24% |
| 2022-12-31 | $17.29 Billion | $24.94 Billion | 1.443x | -2.22% |
| 2021-12-31 | $15.44 Billion | $22.78 Billion | 1.476x | +9.88% |
| 2020-12-31 | $13.10 Billion | $17.59 Billion | 1.343x | +182.36% |
| 2019-12-31 | $-8.17 Billion | $13.32 Billion | -1.630x | -2.56% |
| 2018-12-31 | $-8.45 Billion | $13.43 Billion | -1.590x | -181.35% |
| 2017-12-31 | $5.10 Billion | $9.96 Billion | 1.954x | +28.66% |
| 2016-12-31 | $4.64 Billion | $7.04 Billion | 1.519x | -20.48% |
| 2015-12-31 | $3.94 Billion | $7.54 Billion | 1.910x | -6.25% |
| 2014-12-31 | $1.74 Billion | $3.55 Billion | 2.037x | +46.03% |
| 2013-12-31 | $4.49 Billion | $6.27 Billion | 1.395x | -26.05% |
| 2012-12-31 | $3.36 Billion | $6.34 Billion | 1.887x | +260.37% |
| 2011-12-31 | $11.93 Billion | $6.25 Billion | 0.524x | +65.22% |
| 2010-12-31 | $15.70 Billion | $4.98 Billion | 0.317x | -- |
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various c… Read more